Recent advances against substance abuse

IDrugs

Volumn 6, Issue 7, 2003, Pages 681-687

  Heading, Christine E ^a  

^a OPEN UNIVERSITY   (United Kingdom)

Author keywords

Dependency; Pharmacotherapy; Substance abuse

Indexed keywords

ADROGOLIDE; ALCOHOL; AMFEBUTAMONE; BP 897; BUPRENORPHINE; CENTRAL NERVOUS SYSTEM AGENTS; COCAINE; COCAINE CONJUGATE VACCINE; COCAINE DERIVATIVE; DOPAMINE 3 RECEPTOR LIGAND; DOPAMINE TRANSPORTER LIGAND; GALANTAMINE; KAPPA OPIATE RECEPTOR AGONIST; LIGAND; LONG ACTING DRUG; METHYLPHENIDATE DERIVATIVE; NABI NICVAX; NALMEFENE; NALTREXONE; NERAMEXANE; NICOTINE; NICOTINE VACCINE; NOCAINE; OPIATE; PROBUPHINE; RIMONABANT; TOPIRAMATE; UNCLASSIFIED DRUG; VACCINE; VIGABATRIN;

ALCOHOLISM; CLINICAL TRIAL; COCAINE DEPENDENCE; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG TARGETING; DRUG USE; DRUG WITHDRAWAL; HUMAN; NONHUMAN; OPIATE ADDICTION; PATIENT COMPLIANCE; PHARMACODYNAMICS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REINFORCEMENT; RELAPSE; REVIEW; TOBACCO DEPENDENCE; VACCINATION; WITHDRAWAL SYNDROME;

ANTICONVULSANTS; CLINICAL TRIALS; DOPAMINE UPTAKE INHIBITORS; HUMANS; MOLECULAR STRUCTURE; NARCOTIC ANTAGONISTS; SUBSTANCE-RELATED DISORDERS;

EID: 0042165012     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Diagnostic and Statistical Manual of Mental Disorders DSM-IV. 4th Edition, American Psychiatric Association, Washington, DC, USA (1994): Abs1-208.
2. International Statistical Classified of Diseases and Related Health Problems, Tenth Revision. World Health Organization, Geneva, Switzerland (1992).
3. Altman J, Everitt BJ, Glautier S, Markou A, Nutt D, Orettio R, Phillips GD, Robbins TW: The biological, social and clinical bases of drug addiction: Commentary and debate. Psychopharmacology (1996) 125(4):285-345. Comprehensive and broad-ranging review of topics covered in the paper's title.
4. Heading CE: Common ground in therapy of substance abuse. IDrugs (2001) 4(11):1266-1274.
5. Heading CE: TA-CD. IDrugs (2002) 5(11):1070-1074.
6. Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, Jack L, Fox B: Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine (2002) 20(7-8):1196-1204. Detailed phase I data and preclinical background.
7. Xenova Group plc: Patient dosing begins in phase IIa cocaine administration trial for anti-cocaine addiction vaccine TA-CD. Press Release (2003) April 14.
8. Nabi Pharmaceutical: Nabi Biopharmaceuticals begins European phase I/II trial of NicVAX, investigational vaccine for prevention and treatment of nicotine addiction. Press Release (2003) February 19.
9. Xenova Group plc: Xenova: Interim results announcement 2002. Press Release (2002) August 14.
10. DrugAbuse Sciences Inc: DrugAbuse Sciences' long-term study of Naltrexone depot douses drinking over time. Press Release (2003) DrugAbuse Sciences' long-term study of Naltrexone depot douses drinking over time.
11. Biotie Therapies Corp, Contral Pharma Corp: Biotie Therapies Corporation Interim Report 1.1.-30.6.2002 Contral Pharma Corporation Interim Report 1.1.-30.6.2002 and strategy for the combined company. Press Release (2002) August 29.
12. Ulm RR, Volpicelli JR, Volpicelli LA: Opiates and alcohol self-administration in animals. J Clin Psychiatry (1995) 56(Suppl 7):5-14.
13. 1 receptor antagonist, SR 141716. Eur J Pharmacol (2002) 445(1-2):55-59. Preclinical study including discussion of the role of opioid and cannabinoid receptors in alcohol dependency.
14. Titan Pharmaceuticals Inc: Titan announces Probuphine demonstrates continuous delivery of buprenorphine for eight months in preclinical studies. Press Release (2002) June 07.
15. Titan Pharmaceuticals Inc: Titan reports fourth quarter and year end 2002 results. Press Release (2003) March 27.
16. Alkermes - Science that delivers - Presentation at the JPMorgan H&Q 21st Annual Health Conference. Company Presentation (2003) January 07.
17. Georgetown University Medical Center: New Drug May Help Recovering Cocaine Addicts, Study Shows. Press Release (2002) September 20
18. Woolverton WL, Ranaldi R, Wang Z, Ordway GA, Petukhov P, Kozikowski A: Reinforcing strength of a novel dopamine transporter ligand: Pharmacodynamic and pharmacokinetic mechanisms. J Pharmacol Exp Ther (2002) 303(1):211-217. Preclinical mode of action study.
19. Wilens TE, Faraone SV, Biederman J, Gunawardene S: Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics (2003) 111(1):179-185.
20. Petukhov PA, Zhang J, Kozikowski AP, Wang CZ, Ye YP, Johnson KM, Tella SR: SAR studies of piperidine-based analogues of cocaine. 4. Effect of N-modification and ester replacement. J Med Chem (2002) 45(15):3161-3170.
21. Houlithan WJ, Kelly L, Pankuch J, Koletar J, Brand L, Janowsky A Kopajtic TA: Mazindol analogues as potential inhibitors of the cocaine binding site of the dopamine transporter. J Med Chem (2002) 45(19):4097-4109.
22. Agoston GE, Wu JH, Izenwasser S, George C, Katz J, Kline RH, Newman AH: Novel N-substituted 3α-[bis(4′-fluorophenyl)methoxy]-tropane analogues: Selective ligands for the dopamine transporter. J Med Chem (1997) 40(26):4329-4339.
23. Foster A, Wu H, Chen W, Williams W, Bowen WD, Matsumoto RR, Coop A: 1,4-Dibenzylpiperazines possess anticocaine activity. Bioorg Med Chem Lett (2003) 13(4):749-751.
24. Kimmel HL, Zurich KJ, Ojeda JM, Ginsburg BC, Carroll FI, Howell LL: Characterization of the tropane analog RTI-336, as a behavioural stimulant and dopamine uptake inhibitor in nonhuman primates. Abstr Soc Neurosci (2002) 28:Abs 806.15.
25. Coons S, Javanmard S, Deutsch HM, Collard DM, Schweri MM, Kuhar MJ: Synthesis and pharmacology of potential site specific cocaine abuse treatment agents: Exploration of a secondary phenyl group interaction at the dopamine transporter. 224th ACS Meeting, Boston MA, USA (2002):MEDI 263.
26. Meltzer PC, Wang B, Chen Z, Blundell P, Jayaraman M, Gonzalez MD, George C, Madras BK: Synthesis of 6- and 7-hydroxy-8-azabicyco[3.2.1]octanes and their binding affinity for the dopamine and serotoni transporters. J Med Chem (2001) 44(16):2619-2653.
27. Childress RA, O'Brien CP: Dopamine receptor partial agonists could address duality in cocaine craving. Trends Pharmacol Sci (2000) 21(2):6-9. Detailed summary data on BP-897, in the context of current theories of craving.
28. 3 receptor agonist. Nature (1999) 400(6742):371-375.
29. 3 receptor subtype. J Med Chem (2001) 44(19):3175-3186.
30. DrugAbuse Sciences Inc, Hayward, CA, USA. http://www.drugabusesciences.com
31. Robbins TW, Everitt BJ: Drug addiction: Bad habits add up. Nature (1999) 398(6728):567-570. Comprehensive overview of biological and psychological theories of the basis of substance dependence.
32. Sanofi-Synthélabo: Financial Analysts Meeting: Information meeting - 18 & 19 February, 2003. Company Presentation (2003) February 18-19.
33. 1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol (2002) 13(5-6):451-463. Preclinical behavioral and mode of action study on SR-141716.
34. 1 receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats. Eur J Pharmacol (2002) 443(1-3):95-97. Prelinical behavioral study on SR-141716.
35. Alkermes Inc: Alkermes begins multi-center clinical trial of Medisorb Naltrexone in alcohol-dependent patients. Press Release (2001) April 03.
36. Neumeyer JL, Mello NK, Negus SS, Bidlack JM: κ-Opioid agonists as targets for pharmacotherapies in cocaine abuse. Pharm Acta Helv (2000) 74(2-3):337-344. SAR study prompted by results of behavioral studies.
37. Xiong W, Zhang A, Hilbert JE, Knapp BI, Bidlack JM, Neumeyer JL: Synthesis and opioid receptor affinity of 3-substituted-3-desoxymorphinan analogs. 225th ACS Metting, New Orleans, LA, USA (2003) MEDI 206
38. Schiffer WK, Marsteller D, Dewey SL: Sub-chronic low dose γ-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine. Psychopharmacology (Berl) (2003): epublished ahead of print. Microdialysis in vivo mode of action study.
39. Catalyst Pharmaceutical Partners. Catalyst Pharmaceutical Partners and Brookhaven National Laboratory announce exclusive worldwide license agreement for potential drug addiction treatment. Press Release (2002) October 14.
40. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ: Oral topiramate for the treatment of alcohol dependence: A randomised controlled trial. Lancet (2003) 361(9370):1677-1685. Report of a 150-patient trial of topiramate resulting in reduced alcohol consumption.
41. 2 receptors. IDrugs (2002) 5(8):776-778.
42. Bienkowski P, Koros E, Kostowski W, Danysz W: Effects of N-methyl-D-aspartate receptor antagonists on reinforced and nonreinforced responding for ethanol in rats. Alcohol (1999) 18(2-3):131-137.
43. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM: Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology (1994) 11(2):133-141.
44. Slemmer JE, Martin BR, Damaj MI: Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther (2000) 295(1):321-327.